Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery

Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery

Yonglu Wang1,4, Xueming Li1,2*, Liyao Wang3, Yuanlong Xu1, Xiaodan Cheng1, Ping Wei41College of Pharmacy, Nanjing University of Technology, Nanjing; 2State Key Laboratory of Materials-Oriented Chemical Engineering, Nanjing University of Technology, Nanjing; 3College of Life Science, Anhui Agricultur...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wang YL, Li XM, Wang LY, Xu YL, Cheng XD, Wei P
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2011
Materias:
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/11a3b373d4fc4396b9860e9354c4eba9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:11a3b373d4fc4396b9860e9354c4eba9
record_format dspace
spelling oai:doaj.org-article:11a3b373d4fc4396b9860e9354c4eba92021-12-02T01:13:10ZFormulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery1176-91141178-2013https://doaj.org/article/11a3b373d4fc4396b9860e9354c4eba92011-07-01T00:00:00Zhttp://www.dovepress.com/formulation-and-pharmacokinetic-evaluation-of-a-paclitaxel-nanosuspens-a7863https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Yonglu Wang1,4, Xueming Li1,2*, Liyao Wang3, Yuanlong Xu1, Xiaodan Cheng1, Ping Wei41College of Pharmacy, Nanjing University of Technology, Nanjing; 2State Key Laboratory of Materials-Oriented Chemical Engineering, Nanjing University of Technology, Nanjing; 3College of Life Science, Anhui Agricultural University, Hefei; 4College of Biotechnology and Pharmaceutical Engineering, Nanjing University of Technology, Nanjing, People’s Republic of China *These authors contributed equally to this work.Abstract: Paclitaxel is a diterpenoid isolated from Taxus brevifolia. It is effective for various cancers, especially ovarian and breast cancer. Due to its aqueous insolubility, it is administered dissolved in ethanol and Cremophor® EL (BASF, Ludwigshafen, Germany), which can cause serious allergic reactions. In order to eliminate Cremophor EL, paclitaxel was formulated as a nanosuspension by high-pressure homogenization. The nanosuspension was lyophilized to obtain the dry paclitaxel nanoparticles (average size, 214.4 ± 15.03 nm), which enhanced both the physical and chemical stability of paclitaxel nanoparticles. Paclitaxel dissolution was also enhanced by the nanosuspension. Differential scanning calorimetry showed that the crystallinity of paclitaxel was preserved during the high-pressure homogenization process. The pharmacokinetics and tissue distribution of paclitaxel were compared after intravenous administration of paclitaxel nanosuspension and paclitaxel injection. In rat plasma, paclitaxel nanosuspension exhibited a significantly (P < 0.01) reduced area under the concentration curve (AUC)0–∞ (20.343 ± 9.119 µg · h · mL−1 vs 5.196 ± 1.426 µg · h · mL−1), greater clearance (2.050 ± 0.616 L · kg−1 · h−1 vs 0.556 ± 0.190 L · kg−1 · h−1), and shorter elimination half-life (5.646 ± 2.941 vs 3.774 ± 1.352 hours) compared with the paclitaxel solution. In contrast, the paclitaxel nanosuspension resulted in a significantly greater AUC0–∞ in liver, lung, and spleen (all P < 0.01), but not in heart or kidney.Keywords: high-pressure homogenization, tissue distribution, surfactantWang YLLi XMWang LYXu YLCheng XDWei PDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2011, Iss default, Pp 1497-1507 (2011)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Wang YL
Li XM
Wang LY
Xu YL
Cheng XD
Wei P
Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery
description Yonglu Wang1,4, Xueming Li1,2*, Liyao Wang3, Yuanlong Xu1, Xiaodan Cheng1, Ping Wei41College of Pharmacy, Nanjing University of Technology, Nanjing; 2State Key Laboratory of Materials-Oriented Chemical Engineering, Nanjing University of Technology, Nanjing; 3College of Life Science, Anhui Agricultural University, Hefei; 4College of Biotechnology and Pharmaceutical Engineering, Nanjing University of Technology, Nanjing, People’s Republic of China *These authors contributed equally to this work.Abstract: Paclitaxel is a diterpenoid isolated from Taxus brevifolia. It is effective for various cancers, especially ovarian and breast cancer. Due to its aqueous insolubility, it is administered dissolved in ethanol and Cremophor® EL (BASF, Ludwigshafen, Germany), which can cause serious allergic reactions. In order to eliminate Cremophor EL, paclitaxel was formulated as a nanosuspension by high-pressure homogenization. The nanosuspension was lyophilized to obtain the dry paclitaxel nanoparticles (average size, 214.4 ± 15.03 nm), which enhanced both the physical and chemical stability of paclitaxel nanoparticles. Paclitaxel dissolution was also enhanced by the nanosuspension. Differential scanning calorimetry showed that the crystallinity of paclitaxel was preserved during the high-pressure homogenization process. The pharmacokinetics and tissue distribution of paclitaxel were compared after intravenous administration of paclitaxel nanosuspension and paclitaxel injection. In rat plasma, paclitaxel nanosuspension exhibited a significantly (P < 0.01) reduced area under the concentration curve (AUC)0–∞ (20.343 ± 9.119 µg · h · mL−1 vs 5.196 ± 1.426 µg · h · mL−1), greater clearance (2.050 ± 0.616 L · kg−1 · h−1 vs 0.556 ± 0.190 L · kg−1 · h−1), and shorter elimination half-life (5.646 ± 2.941 vs 3.774 ± 1.352 hours) compared with the paclitaxel solution. In contrast, the paclitaxel nanosuspension resulted in a significantly greater AUC0–∞ in liver, lung, and spleen (all P < 0.01), but not in heart or kidney.Keywords: high-pressure homogenization, tissue distribution, surfactant
format article
author Wang YL
Li XM
Wang LY
Xu YL
Cheng XD
Wei P
author_facet Wang YL
Li XM
Wang LY
Xu YL
Cheng XD
Wei P
author_sort Wang YL
title Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery
title_short Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery
title_full Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery
title_fullStr Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery
title_full_unstemmed Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery
title_sort formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery
publisher Dove Medical Press
publishDate 2011
url https://doaj.org/article/11a3b373d4fc4396b9860e9354c4eba9
work_keys_str_mv AT wangyl formulationandpharmacokineticevaluationofapaclitaxelnanosuspensionforintravenousdelivery
AT lixm formulationandpharmacokineticevaluationofapaclitaxelnanosuspensionforintravenousdelivery
AT wangly formulationandpharmacokineticevaluationofapaclitaxelnanosuspensionforintravenousdelivery
AT xuyl formulationandpharmacokineticevaluationofapaclitaxelnanosuspensionforintravenousdelivery
AT chengxd formulationandpharmacokineticevaluationofapaclitaxelnanosuspensionforintravenousdelivery
AT weip formulationandpharmacokineticevaluationofapaclitaxelnanosuspensionforintravenousdelivery
_version_ 1718403180984795136

Ejemplares similares